Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative, first-in-class medicines, has announced its participation in the 2024 Cantor Global Healthcare Conference.
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative, first-in-class medicines, has announced its participation in the 2024 Cantor Global Healthcare Conference. Justin Renz, the company's Chief Financial and Operations Officer, will engage in a fireside chat on Thursday, September 19, 2024, at 9:10 A.M. Eastern Time in New York City.
Interested parties can access a live webcast of the panel presentation through the Events and Presentations page on the Ardelyx website. For those unable to attend, a replay of the fireside chat will be available on the company's website for 30 days following the event, providing an opportunity for investors and stakeholders to gain insights into Ardelyx's operations and future plans.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ARDX
The recorded move for ARDX in the trading session of this news was +1.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:10 A.M. Eastern Time in New York City.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.